Influenza, novel coronavirus infection and cardiovascular diseases

Boytsov S.A.

doi:https://doi.org/10.17116/Cardiobulletin2021160115

Close metadata

Recommended articles:

Risk factors and adverse outcomes of cardiovascular diseases in people with high normal blood pressure of the Ryazan region. (5-year prospective follow-up). Russian Journal of Preventive Medicine. 2025;(2):31-37

A rational approach to the prevention and treatment of ARVI and influenza, as a medico-economic and socially significant problem of the XXI century. Journal of Respiratory Medicine. 2025;(1):43-48

Post-COVID syndrome: organizing COVID-19-associated pneumonia. Clinical case. Journal of Respiratory Medicine. 2025;(1):65-72

10-year dynamics of cardiovascular status in combination with coronary angiography data in men of working age in the Arctic region of residence and the south of the Tyumen region. Russian Journal of Preventive Medicine. 2025;(4):30-38

Study of the levocarnitine efficacy for the treatment of moderate cognitive impairment in patients with hypertension. Russian Journal of Preventive Medicine. 2025;(4):45-50

Post-exposure prophylaxis of influenza and ARVI. Results of a double-blind, placebo-controlled clinical trial of Meglumine acridone acetate and its pharmacoeconomic rationale. Russian Journal of Preventive Medicine. 2025;(4):57-66

Triglycerides-Glucose Index as an integral biomarker of insulin resistance and cardiovascular diseases. Russian Journal of Preventive Medicine. 2025;(5):124-129

Contribution of the Russian Academy of Sciences Academician R.G. Oganov to the development of the domestic preventive cardiology. Russian Journal of Preventive Medicine. 2025;(6):7-10

Hypertensive disorders of pregnancy as a risk factor for chronic non-communicable diseases. Russian Journal of Preventive Medicine. 2025;(6):114-119

Features of care of patients with cardiovascular diseases and cognitive disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):99-104

Abstract:

The author demonstrates significant influence of influenza and novel coronavirus infection epidemics on in-hospital and mid-term mortality of patients with cardiovascular diseases. This is the result of direct aggravation of pathological processes under infections and reduced availability of medical care during epidemics. The relationship between the incidence of influenza and cardiovascular mortality persists throughout 2 months after the end of epidemic («delayed mortality»). Preliminary evidence suggests a similar association between previous coronavirus infection and higher risk of cardiovascular mortality within several months after recovery. Observational and randomized studies revealed that influenza vaccination reduces the risk of cardiovascular complications and cardiovascular mortality.

Keywords:

influenza

novel coronavirus infection

cardiovascular diseases

Authors:

Boytsov S.A.

Chazov National Medical Research Center of Cardiology

ORCID: 0000-0001-6998-8406

Received:

23.02.2021

Accepted:

15.03.2021

Close metadata

References:

Omran AR. The epidemiologic transition. A theory of the epidemiology of population change. The Milbank Memorial Fund Quarterly. 1971;49(4):509-538. https://doi.org/10.1111/j.1468-0009.2005.00398.x
Collins SD. Excess Mortality from Causes Other than Influenza and Pneumonia during Influenza Epidemics. Public Health Reports. 1932;47(46):2159-2179. https://doi.org/10.2307/4580606
Sprenger MJ, Mulder PG, Beyer WE, Van Strik R, Masurel N. Impact of influenza on mortality in relation to age and underlying disease. 1967—1989. International Journal of Epidemiology. 1993;22(2):334-340. https://doi.org/10.1093/ije/22.2.334
Saltykova TS. Delayed mortality in influenza and the tactics of vaccination of this infection among the elderly. Epidemiologiya i infekcionnye bolezni. 2008;2:55-57. (In Russ.).
Madjid M, Miller C, Zarubaev V, Marinich IG, Kiselev OI, Lobzin YV, Filippov AE, Casscells SW. Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34 892 subjects. European Heart Journal. 2007;28(10):1205-1210. https://doi.org/10.1093/eurheartj/ehm035
Warren-Gash C, Bhaskaran K, Hayward A, Leung GM, Lo SV, Wong CM, Ellis J, Pebody R, Smeeth L, Cowling BJ. Circulating influenza virus, climatic factors, and acute myocardial infarction: a Time Series Study in England and Wales and Hong Kong. The Journal of Infectious Diseases. 2011;203(12):1710-1718. https://doi.org/10.1093/infdis/jir171
Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. The New England Journal of Medicine. 2004;351(25):2611-2618. https://doi.org/10.1056/NEJMoa041747
Boytsov SA, Loukianov MM, Platonova EV, Gorbunov VM, Romanchuk SV, Nazarova OA, Belova OA, Kravtsova EA, Dovgalevsky PYa, Furman NV, Mironova AA, Dolotovskaya PV, Nekrasov AV, Puchkova NG, Abramova MA, Belova EN, Klyashtorny VG, Deev AD. Efficiency of influenza vaccination in patients with circulatory system diseases under dispensary observation in outpatient clinics: prospective follow-up monitoring data. Racional’naja farmakoterapija v kardiologii. 2016;12(6):703-710. (In Russ.). https://doi.org/10.20996/1819-6446-2016-12-6-703-710
Rodrigues BS, David C, Costa J, Ferreira JJ, Pinto FJ, Caldeira D. Influenza vaccination in patients with heart failure: A systematic review and meta-analysis of observational studies. Heart. 2020;106(5):350-357. https://doi.org/10.1136/heartjnl-2019-315193
Warren-Gash C, Smeeth L, Hayward AC. Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: a systematic review. The Lancet. Infectious Diseases. 2009;9(10):601-610. https://doi.org/10.1016/S1473-3099(09)70233-6
Demkina AE, Morozov SP, Vladzymyrskyy AV, Kljashtorny VG, Guseva OI, Pugachev PS, Artemova OR, Reshetnikov RV, Gombolevskiy VA, Ryabinina MN. Risk factors for outcomes of COVID-19 patients: an observational study of 795 572 patients in Russia. medRxiv [Preprint]. 2020. https://doi.org/10.1101/2020.11.02.20224253
Zanettini C, Omar M, Dinalankara W, Imada EL, Colantuoni E, Parmigiani G, Marchionni L. Influenza Vaccination and COVID19 Mortality in the USA. medRxiv [Preprint]. 2020. https://doi.org/10.1101/2020.06.24.20129817
Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, Cuomo-Dannenburg G, Thompson H, Walker PGT, Fu H, Dighe A, Griffin JT, Baguelin M, Bhatia S, Boonyasiri A, Cori A, Cucunubá Z, FitzJohn R, Gaythorpe K, Green W, Hamlet A, Hinsley W, Laydon D, Nedjati-Gilani G, Riley S, van Elsland S, Volz E, Wang H, Wang Y, Xi X, Donnelly CA, Ghani AC, Ferguson NM. Estimates of the severity of coronavirus disease 2019: a model-based analysis. The Lancet. Infectious Diseases. 2020;20(6):669-677. https://doi.org/10.1016/S1473-3099(20)30243-7
Centers for Disease Control and Prevention. Estimated Influenza Illnesses, Medical Visits, Hospitalizations, and Deaths in the United States — 2018—2019 Influenza Season. Accessed May 28, 2020. https://www.cdc.gov/flu/about/burden/2018-2019.html
Centers for Disease Control and Prevention. Excess Deaths Associated with COVID-19. Provisional Death Counts for Coronavirus Disease (COVID-19). Accessed May 28, 2020. https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess_deaths.htm#dashboard
Eurostat. Deaths by Age and Sex. Accessed March 08, 2021. https://ec.europa.eu/eurostat/databrowser/view/demo_magec/default/table?lang=en
Eurostat. Deaths by Week and Sex. Accessed March 08, 2021. https://ec.europa.eu/eurostat/databrowser/view/demo_r_mwk_ts/default/table?lang=en
Wu J, Mamas MA, Mohamed MO, Kwok CS, Roebuck C, Humberstone B, Denwood T, Luescher T, de Belder MA, Deanfield JE, Gale CP. Place and causes of acute cardiovascular mortality during the COVID-19 pandemic. Heart. 2021;107(2):113-119. https://doi.org/10.1136/heartjnl-2020-317912
Nef HM, Elasser A, Mollmann H, Abdel-Hadi M, Bauer T, Brück M, Eggebrecht H, Ehrlich JR, Ferrari MW, Fichtlscherer S, Hink U, Hölschermann H, Kacapor R, Koeth O, Korboukov S, Lamparter S, Laspoulas AJ, Lehmann R, Liebetrau C, Plücker T, Pons-Kühnemann J, Schächinger V, Schieffer B, Schott P, Schulze M, Teupe C, Vasa-Nicotera M, Weber M, Weinbrenner C, Werner G, Hamm CW, Dörr O; CoVCAD-Study Group. Impact of the COVID-19 pandemic on cardiovascular mortality and catherization activity during the lockdown in central Germany: an observational study. Clinical Research in Cardiology. 2021;110(2):292-301. https://doi.org/10.1007/s00392-020-01780-0
Brant LCC, Nascimento BR, Teixeira RA, Lopes MACQ, Malta DC, Oliveira GMM, Ribeiro ALP. Excess of cardiovascular deaths during the COVID-19 pandemic in Brazilian capital cities. Heart. 2020;106(24):1898-1905. https://doi.org/10.1136/heartjnl-2020-317663
Faust JS, Lin Z, Wright NK, Di Iorio MA, Walsh CD, Krumholz HM. Heart disease mortality during the early pandemic period in the United States. medRxiv. [Preprint]. 2020.08.16.20175406. https://doi.org/10.1101/2020.08.16.20175406
Ayoubkhani D, Khunti K, Nafilyan V, Maddox T, Humberstone B, Diamond I, Banerjee A. Epidemiology of post-COVID syndrome following hospitalisation with coronavirus: a retrospective cohort study. medRxiv. [Preprint]. 2021.01.15.21249885. https://doi.org/10.1101/2021.01.15.21249885
Khan MS, Shahid I, Anker SD, Solomon SD, Vardeny O, Michos ED, Fonarow GC, Butler J. Cardiovascular implications of COVID-19 versus influenza infection: a review. BMC Medicine. 2020;18(1):403. https://doi.org/10.1186/s12916-020-01816-2
Li J, Guo T, Dong D, Zhang X, Chen X, Feng Y, Wei B, Zhang W, Zhao M, Wan J. Defining heart disease risk for death in COVID-19 Infection. QJM. 2020;113(12):876-882. https://doi.org/10.1093/qjmed/hcaa246
Impact of Cardiovascular Disease on Outcomes among Hospitalized COVID-19 Patients: Results From >14,000 Patients across the U.S. Accessed March 08, 2021. https://www.dicardiolog.com/content/covid-19-patients-cardiovascular-disease-have-hospital-mortality-rates-%C2%A025-38-percent
Del Pinto R, Ferri C, Mammarella L, Abballe S, Dell’Anna S, Cicogna S, Grassi D, Sacco S, Desideri G. Increased cardiovascular death rates in a COVID‐19 low prevalence area. Journal of Clinical Hypertension. 2020;22(10):1932-1935. https://doi.org/10.1111/jch.14013